Responsible Clinician Notification:

**From:** Mayo Clinic IRB  
**To:** Michael Joyner  
**CC:** Kylie Andersen, Philippe Bauer, Katelyn Bruno, Zachary Buchholtz, Joshua Culberson, Juan Diaz Soto, Adam Eggert, DeLisa Fairweather, Jennifer Ferguson, Starr Guzman, Vitaly Herasevich, Julianna Higa, Michael Joyner, Allan Klompas, Tessa Kroeninger, Claudia Libertin, Jaime Long, Jose Malavet, William Morice, Brenna Murphy, Laura Pacheco-Spann, Angela Patterson, Michaela Pletsch, Robert Rea, Riley Regimbal, Juan Ripoll Sanz, Shelly Roberts, Matthew Sexton, Elitza Theel, Kristine Tree, Camille Van Buskirk, Noud van Helmond, Matthew Vogt, Emily Whelan
Jeffrey Winters

**Re:** Continuing Review # [PR20-003312-01](#)

**Application Title:** Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

**IRB#: 20-003312**

The following is an excerpt from the minutes of the Mayo Clinic Institutional Review Boards (IRB Friday) meeting dated 3/26/2021:

**DECISION:** The Committee reviewed the continuing report and approved the continuation of the above referenced program. This approval is valid for one year unless during that time the IRB determines that it is appropriate to halt or suspend the program earlier. IRB approval will expire on March 25, 2022.

**REVIEW:** The Committee noted 105,717 subjects have been accrued to date. The Committee noted the internal and external UPIRTSOs summary and noted no change in the risk/benefit ratio. The Committee noted the non-UPIRTSOs summary and noted no change in the risk/benefit ratio. The Committee accepts the appointment of the Mayo Clinic IRB as the IRB of Record for the Relying Organizations which include all sites agreeing to participate via [www.uscovidplasma.org](http://www.uscovidplasma.org) (2,232 sites), and notes receipt of the fully executed IRB Authorization Agreement.

**CONSENT:** The Committee approved waiver of the requirement to obtain informed consent in accordance with 45 CFR 46.116 as justified by the Investigator, and waiver of HIPAA authorization in accordance with applicable HIPAA regulations.

**REMININDER:** The Committee:

- Reminds the investigator to immediately submit to the IRB any Data Safety Monitoring Board (DSMB) correspondence recommending suspension or other alteration of the research, or identifying new safety concerns, as well as submitting all other DSMB communications at the time of the next continuing review.

Attachments (if applicable):

<table>
<thead>
<tr>
<th>name</th>
<th>version</th>
<th>dateCreated</th>
<th>dateModified</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are no items to display</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Drake, Matthew M.D., Chair  
Rebecca Lowy, Correspondent  
Mayo Clinic Institutional Review Boards  
IRB Friday